Aurobindo Pharma Limited (AUROPHARMA) - Total Assets
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) holds total assets worth Rs525.46 Billion INR (≈ $5.68 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Aurobindo Pharma Limited shareholders equity for net asset value and shareholders' equity analysis.
Aurobindo Pharma Limited - Total Assets Trend (2004–2025)
This chart illustrates how Aurobindo Pharma Limited's total assets have evolved over time, based on quarterly financial data.
Aurobindo Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Aurobindo Pharma Limited's total assets of Rs525.46 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs29.20 Billion | 16.5% |
| Accounts Receivable | Rs57.61 Billion | 11.6% |
| Inventory | Rs105.44 Billion | 21.2% |
| Property, Plant & Equipment | Rs154.55 Billion | 31.0% |
| Intangible Assets | Rs36.21 Billion | 7.3% |
| Goodwill | Rs6.18 Billion | 1.2% |
Asset Composition Trend (2004–2025)
This chart illustrates how Aurobindo Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aurobindo Pharma Limited (AUROPHARMA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aurobindo Pharma Limited's current assets represent 54.6% of total assets in 2025, an increase from 51.4% in 2004.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2025, up from 3.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 1.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 31.0% of total assets.
Aurobindo Pharma Limited Competitors by Total Assets
Key competitors of Aurobindo Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
Aurobindo Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 1.83 | 1.59 |
| Quick Ratio | 1.13 | 1.10 | 0.80 |
| Cash Ratio | 0.57 | 0.48 | 0.00 |
| Working Capital | Rs131.48 Billion | Rs118.85 Billion | Rs65.85 Billion |
Aurobindo Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Aurobindo Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 10.5% |
| Total Assets | Rs497.85 Billion |
| Market Capitalization | $8.73 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Aurobindo Pharma Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aurobindo Pharma Limited's assets grew by 10.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aurobindo Pharma Limited (2004–2025)
The table below shows the annual total assets of Aurobindo Pharma Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs497.85 Billion ≈ $5.38 Billion |
+10.46% |
| 2024-03-31 | Rs450.72 Billion ≈ $4.87 Billion |
+12.99% |
| 2023-03-31 | Rs398.90 Billion ≈ $4.31 Billion |
+17.59% |
| 2022-03-31 | Rs339.22 Billion ≈ $3.67 Billion |
+0.20% |
| 2021-03-31 | Rs338.54 Billion ≈ $3.66 Billion |
+17.03% |
| 2020-03-31 | Rs289.28 Billion ≈ $3.13 Billion |
+9.35% |
| 2019-03-31 | Rs264.54 Billion ≈ $2.86 Billion |
+25.37% |
| 2018-03-31 | Rs211.01 Billion ≈ $2.28 Billion |
+29.86% |
| 2017-03-31 | Rs162.49 Billion ≈ $1.76 Billion |
+2.07% |
| 2016-03-31 | Rs159.20 Billion ≈ $1.72 Billion |
+23.27% |
| 2015-03-31 | Rs129.14 Billion ≈ $1.40 Billion |
+36.09% |
| 2014-03-31 | Rs94.90 Billion ≈ $1.03 Billion |
+30.39% |
| 2013-03-31 | Rs72.78 Billion ≈ $787.07 Million |
+16.68% |
| 2012-03-31 | Rs62.38 Billion ≈ $674.58 Million |
+6.22% |
| 2011-03-31 | Rs58.72 Billion ≈ $635.06 Million |
+22.56% |
| 2010-03-31 | Rs47.91 Billion ≈ $518.16 Million |
+13.36% |
| 2009-03-31 | Rs42.26 Billion ≈ $457.08 Million |
+16.29% |
| 2008-03-31 | Rs36.34 Billion ≈ $393.06 Million |
+3.65% |
| 2007-03-31 | Rs35.06 Billion ≈ $379.21 Million |
+30.38% |
| 2006-03-31 | Rs26.89 Billion ≈ $290.85 Million |
+26.28% |
| 2005-03-31 | Rs21.30 Billion ≈ $230.33 Million |
+14.14% |
| 2004-03-31 | Rs18.66 Billion ≈ $201.79 Million |
-- |
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more